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Abstract P-glyeoprotein is a plasma-membrane glycoprotein 
which confers multidrug-resistance on cells and displays ATP- 
driven drug-pumping in vitro. It contains two nucleotide-binding 
domains, and its structure places it in the 'ABC transporter' 
family. We review recent evidence that both nucleotide-sites bind 
and hydrolyse Mg-ATP. The two catalytic sites interact strongly. 
A minimal scheme for the MgATP hydrolysis reaction is pre- 
sented. An alternating catalytic sites scheme is proposed, in which 
drug transport is coupled to relaxation of a high-energy catalytic 
site conformation generated by the hydrolysis step. Other ABC 
transporters may show similar catalytic features. 
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I. Introduction 
P-Glycoprotein (Pgp) (also called multidrug-resistance pro- 
tein) is a plasma-membrane glycoprotein which confers mul- 
tidrug-resistance (MDR) phenotype on cells [1-4]. It is of con- 
siderable interest because it provides one mechanism of resis- 
tance to chemotherapy in cancer [5-7] and is also a prominent 
member of the 'ABC transporter' family of membrane proteins 
[6,81, 
Earlier work on Pgp utilized cell and molecular biology 
methodologies to describe its structure and function. Recently 
sufficient experimental material has been obtained, in the form 
of Pgp-enriched membrane preparations and purified Pgp, to 
facilitate biochemical investigations, which have revealed e- 
tails of catalytic, ATP hydrolysis properties. This review sum- 
marises recent work on catalysis, with the hope that it will 
stimulate further understanding of Pgp and ABC transporters 
generally. 
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2. Indications that Pgp hydrolyses ATP 
Early work which established that Pgp acts by excluding 
cytotoxic drugs from cells suggested also that it utilizes energy 
from ATP [9,10], and subsequent reports confirmed this. Re- 
cent papers [11-16] present evidence for ATP-driven drug- 
pumping by Pgp in vitro, with non-hydrolysable ATP analogs 
being ineffective. 
The amino acid sequence suggests Pgp might be an ATPase. 
Pgp is a single polypeptide o f -  1280 residues with typical ABC 
transporter structure profile, conveniently represented as 
I TMD1-NBS1-TMD2-NBS2}, where TMD stands for 'trans- 
membrane domain' (containing six trans-membrane s-helices) 
and NBS stands for 'nucleotide-binding site'. Each NBS con- 
tains 'Homology A' and 'Homology B' consensus equences 
[17], diagnostic of nucleotide-binding and common in ATPase 
enzymes. NBSI and NBS2 are strongly homologous to each 
other, with -66% identical residues in human and rodent Pgp. 
These indications timulated studies to establish whether 
membrane-bound and purified Pgp catalyse ATP hydrolysis. 
3. Demonstration and characterization of ATPase activity 
A crude membrane fraction from baculovirus-infected Sf9
cells showed considerable ATPase activity when the virus car- 
ried human MDR 1 (Pgp) cDNA, but not with 'sham' virus [18]. 
ATPase activity was stimulated by verapamil, a known 'modu- 
lator' or 'chemo-sensitizer' of Pgp-mediated MDR phenotype, 
and also by the drugs vincristine, vinblastine, and daunomycin, 
to which Pgp confers resistance in cancer cells. A1-Shawi and 
Senior [19] obtained purified plasma membranes which were 
highly-enriched in Pgp from multidrug-resistant Chinese ham- 
ster ovary cells. These membranes showed substantial ATPase 
activity, referable to Pgp, which was stimulated by verapamil 
and a range of other drugs. 
Chinese hamster Pgp was solubilized in detergent, purified 
to homogeneity, and reconstituted in proteoliposomes [20,21]. 
The pure reconstituted Pgp showed substantial drug-stimulated 
ATPase activity. Human Pgp was also purified to homogeneity 
and reconstituted in proteoliposomes with retention of activity 
[22], and active, purified, soluble Chinese hamster Pgp in the 
t~rm of lipid-protein aggregates was described [23]. 
Membrane-bound and purified Pgp preparations show simi- 
lar enzymatic properties. (Pgp occurs as three isoforms in ro- 
dents and two in human. Work on ATPase of Chinese hamster 
Pgp is referable to isoform-1 (Pgpl), the isoform overexpressed 
in the cell lines used [24,25]. Studies on ATPase of human Pgp 
used MDR1 isoform which confers MDR and is equivalent to 
Chinese hamster Pgpl. No significant differences between 
human MDR1 and Chinese hamster Pgpl have been seen.) 
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Fig. I. Scheme for vanadate-inhibition of P-glycoprotein ATPase activity and AT}' hydrolysis. 
+ MgADP 
Maximal, drug-stimulated Mg-ATP hydrolysis turnover 
rate -- 1~20 s l Km(Mg-ATP) =-1  mM. k~a,/Km(Mg-ATP) = 
~104 M t 's -~. Only a single Km(Mg-ATP ) is apparent, 
which does not materially change in presence of drugs. Mg- 
ADP and Mg-AMPP-NP are competitive inhibitors with K~ 
values 0.35-0.70 mM. A diverse range of nucleoside tri- 
phosphates i hydrolysed. Overall we conclude that Mg-ATP 
is the physiological substrate and it is hydrolysed at a catalytic 
site or sites which have low affinity and low specificity for 
nucleotides [26]. 
Pgp preparations (membranes or purified) show significant 
'basal' ATPase activity in absence of drug, the origin of which 
is not yet understood. It might be due to activation by en- 
dogenous transport site ligand (lipid?). The degree of enhance- 
ment of ATPase by drugs varies among preparations. With 
verapamil, which elicits maximal turnover, the degree of stimu- 
lation above basal ranges from 2.5- to ll-fold. It has been 
established that the lipid milieu affects both basal activity and 
degree of stimulation by drugs [23,27,28]. 
Degree of glycosylation does not appear to affect catalysis. 
Human Pgp expressed in SO or human cell-lines (above) 
showed similar ATPase characteristics. It may be noted that 
Pgp confers drug-resistance in yeast and Escherichia coli [29 
31]. The role of phosphorylation i  modulating Pgp activity 
remains unclear. Mutational analyses failed to detect a critical 
role for phosphorylation sites [32]. A recent report suggested 
that phosphorylation increases ATPase activity of Pgp in mem- 
branes by ~ 2-fold [33]. Calmodulin was shown to modulate drug 
transport by Pgp in membrane vesicles [34], and may signifi- 
cantly affect ATPase activity. [t is apparent herefore that a 
number of identified entities, including lipid environment, 
phosphorylation and calmodulin may modulate Pgp ATPase 
activity, although their physiological roles have yet to be de- 
fined. 
Several potent inhibitors of Pgp ATPase activity have been 
identified (Table 1) and have been valuable in characterisation. 
Also listed in Table 1 are compounds known to potently inhibit 
other membrane ATPases, which do not markedly inhibit Pgp, 
and hence are useful tools for distinguishing Pgp activity. 
Mutations affect ATPase activity significantly. Several muta- 
tions located in the TMD were shown to affect basal and 
drug-stimulated ATPase activity of purified, reconstituted 
human Pgp [22]. These included F335A~ which gave considera- 
ble increase in ATPase, and F978A which gave large decrease. 
G141V, G185V and G830V caused relative changes in degree 
of activation of ATPase by vinblastine, verapamil and colchic- 
inc. Rao [35] studied the G185V mutation in human Pgp using 
the membrane fraction from St9 cells, and obtained similar 
results. It was apparent from these studies that functional com- 
munication between the TMD and catalytic sites was retained, 
and that relative ffects of mutations on ATPase activity paral- 
leled those on drug-exclusion seen in whole cells. Mutations 
occurring within the NBS will be discussed later. 
4. Evidence that both predicted nucleotide-binding sites bind 
Mg-ATP 
N EM inactivates Pgp ATPase potently and reacts covalently 
at two sites. Mg-ATP protects against inactivation and reac- 
tion. Labeling with radioactive NEM occurred equally in N- 
and C-terminal halves of the molecule [21,25]. (Assay of distri- 
bution of label between NBS1 and NBS2 is facilitated by mild 
trypsin digestion, which splits Pgp into N- and C-terminal 
'halves' [36].) From these findings it was postulated that NEM 
reacts with two specific Cys residues, located in the Homology 
A sequences of NBS1 and NBS2 [25]. The Homology A se- 
quence in NBS1 is GNSGCGKS and that in NBS2 is 
GSSGCGKS. Loo and Clarke [37] proved that the highlighted 
Table 1 
Inhibition of ATPase activity of P-glycoprotein 
Compound EC50 a'b 
Orthovanadate (Vi) 10 ~tM 
N-ethylmaleimide (NEM) 5/,tM 
NBD-CI 10 pM 
Bafilomycin A~ 1 pM c 
Fluoroaluminate 60 pM 
EGTA > 1 mM 
Ouabain > l0 mM 
DCCD 0.2 mM 
NaN, > 50 mM 
FITC 0.2 mM 
"EC~,, = concentration for 50% inhibition. 
bExcept as noted, values are those measured in our laboratory with 
plasma-membrane or purified reconstituted Chinese hamster Pgp 
[19,21,25]. Average numbers are presented. 
"Data for purified Pgp from [23]. Concanamycin A and B inhibited with 
similar potency. Bafilomycin Al inhibited membrane Pgp by 50% at 
10pM. 
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Cys residues were the ones that reacted with NEM. They gen- 
erated Cys-free Pgp (which retained normal activity in regard 
to MDR phenotype and ATPase) then re-inserted the Homol- 
ogy A Cys residues eparately. Each of the two resultant mu- 
tant Pgp molecules howed NEM-sensitive ATPase, and Mg- 
ATP protected with similar efficacy in each case. These data 
show that MgATP binds to both NBS1 and NBS2, with ap- 
proximately equal affinity. 
Mg-8-azido-ATP is a UV-photoactivated analog of Mg- 
ATE often used to label Mg-ATP binding sites of proteins. It 
is a good hydrolysis ubstrate for Pgp, with K,, and koa,/Km 
values similar to Mg-ATP [21,25], At saturating concentra- 
tions, Mg-8-azido-ATP was seen to label Pgp with stoichiom- 
etry approaching 2 mol/mol [25]. The label was equally distrib- 
uted in NBS1 and NBS2 and labeling was protected by 
MgATR These results show that both NBSI and NBS2 bind 
Mg-8-azido-ATP and Mg-ATP. 
Loo and Clarke [38] constructed 'half-molecules' of Pgp cor- 
responding to {TMD1 plus NBS1} and {TMD2 plus NBS2}, 
respectively, and expressed them in Sf9 cells. Both showed 
ATPase activity, indicating that both NBS 1 and NBS2 have the 
potential capability to bind and hydrolyse ATE Basal ATPase 
was similar in both half-molecules, but there was no stimulation 
by drugs except when they were co-expressed. Thus, interaction 
between the two half-molecules was critical for normal func- 
tion. 
5. Evidence that the two nucleotide-binding sites interact 
Work was described above in which mutant Pgp proteins 
containing a single Cys located in either the Homology A se- 
quence of NBSI or NBS2 were constructed [37]. Reaction of 
either Cys with NEM was seen to eliminate all ATPase activity, 
showing that inactivated NBSI blocked hydrolysis of Mg-ATP 
in NBS2 or vice versa. This argues strongly that the two NBS 
interact. 
NBD-C1 inactivated Pgp ATPase and reacted covalently with 
stoichiometry of 1.1 mol/mol. Inactivation and labeling were 
protected by Mg-ATP [l 9] and covalent incorporation ofNBD- 
C1 occurred predominantly in NBS2 [21], Since reaction of 
NBD-C1 in NBS2 eliminated all ATPase activity, inactivated 
NBS2 must interact with NBS1 to block Mg-ATP hydrolysis 
in that site. 
Azzaria et al. [39] introduced mutations (Gly--*Ala or 
Lys--,Arg) into the Homology A sequences of either NBS1 or 
NBS2. Each mutation was sufficient to block drug-transport by
Pgp in cells. Thus it was apparent hat both nucleotide sites 
must be intact for normal function. Loo and Clarke [37] ex- 
tended this approach, showing that the mutations K433M, 
K1076M, G432S and G1075S in the Homology A sequences of 
either NBS1 or NBS2 in human Pgp abolish drug-exclusion 
capability in cells and eliminate ATPase activity in membranes. 
This argues strongly that the two catalytic sites must interact, 
and coincidentally demonstrates an obligatory link between 
ATPase and drug-exclusion activity. 
Persuasive data showing interaction between ucleotide sites 
has come from vanadate-trapping experiments. It was found 
that orthovanadate (Vi) inhibits Pgp ATPase by trapping nucle- 
otide in a catalytic site [40]. Whether Mg-ATP or Mg-ADP was 
initially preincubated with Pgp and Vi, the resultant rapped 
nucleotide was ADR showing that in the case of Mg-ATP, at 
least one turnover occurred before onset of inhibition. Reacti- 
vation of vanadate-inhibited Pgp was slow, and correlated well 
with release of trapped nucleotide. Significantly, vanadate-trap- 
ping of ADP at just one catalytic site per Pgp was sufficient to 
block all ATPase and release of the single trapped ADP regen- 
erated ATPase activity fully. 
Mg-8-azido-ATP substituted well for Mg-ATP in vanadate- 
trapping experiments, and allowed determination of which 
NBS was the one at which trapping occurred [41]. The proce- 
dure followed was to incubate radioactive Mg-8-azido-ATP 
with Pgp and Vi, separate inhibited Pgp from free Vi and 
nucleotide, subject it to UV-photoactivation, and determine 
distribution of label between N- and C-halves of the protein. 
The label was distributed equally, showing that vanadate-trap- 
ping occurred non-selectively in both NBS1 and NBS2. This 
experiment shows that both nucleotide-sites hydrolyze 8-azido- 
ATP and that trapping of nucleotide at either catalytic site 
completely blocks hydrolysis at both sites. The two sites have 
approximately the same apparent affinity for 8-azido-ATP, 
consistent with the fact that there is only a single apparent Km 
for Mg-8-azido-ATP or MgATP [21,25]. 
6. The ATP hydrolysis reaction 
We have not detected any covalent Pgp-phosphate catalytic 
intermediate species and have concluded that the ATPase reac- 
tion does not involve one. Rather, experiments described above 
suggested the scheme for vanadate-inhibition shown in Fig. 1, 
from which a minimal scheme for Mg-ATP hydrolysis emerges. 
The major findings were as follows. First, incubation of Pgp 
with Vi and either Mg-ATP or Mg-ADP induces inhibition but 
the trapped nucleotide is ADP in both cases. Second, Vi com- 
petes with P~ but not with Mg-ATP or Mg-ADP. Pi is a weakly- 
binding ligand with K~ -- ~ 100 raM. Third, vanadate-inhibition 
occurs rapidly with Mg-ATP but slowly with Mg-ADP. Fourth, 
P. is a weak, mixed-type inhibitor of ATPase activity [41]. 
We propose that vanadate-inhibition occurs by steps 
(k,~k+2"k+3"k+5) (with MgATP) or by steps (k_4-k+5) (with 
MgADP), and that ATP hydrolysis occurs by steps 
(k+l-k+2.k+3.k+4) (see Fig. 1). Since reactivation of vanadate- 
inhibited Pgp is slow (kap p = 1.4x 10 -4 s -~ at 37°C) and overall 
ATPase turnover is - 10-20 s 1 at 37°C, step k-5 is rate-limiting 
in reactivation. Given the chemical analogy between Vi and P~, 
there are strong reasons to think that Vi in the Pgp. Mg- 
ADP.Vi complex occupies the same position as P~ 
derived from MgATP during hydrolysis, and that the Pgp. Mg- 
ADP' Vi complex resembles the transition state conformation 
of the normal reaction pathway, 
7. Alternation of the two catalytic sites in catalysis 
The finding that vanadate-trapping of nucleotide at either 
catalytic site blocks ATP hydrolysis at both sites suggests that 
when one site enters the transition state conformation the other 
cannot do so, and implies that the sites may undergo ATP 
hydrolysis alternately. Mutations or chemical modifications 
which inactivate one catalytic site also block catalysis at the 
other, intact site. In these cases, if alternation of sites is re- 
quired, then catalysis would halt after a single turnover in the 
intact site. 
Fig. 2 depicts a postulated alternating catalytic sites cycle, 
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Fig. 2. Postulated alternating catalytic sites cycle of ATP hydrolysis by 
P-glycoprotein. Rectangles, represent the two Pgp TMD (trans-mem- 
brane domains); Circles, squares, and hexagon, represent different con- 
formations of the N- and C-catalytic sites (NBSI and NBS2, respec- 
tively). (Top left) The N-catalytic site is empty, the C-catalytic site has 
bound ATE drug is bound at inside-facing transport site. (Top right) 
We suggest hat ATP binding at the N-site allows ATP hydrolysis at 
the C-site, inducing a conformation at the C-site which prohibits hy- 
drolysis at the N-site. The conformation atthe C-site immediately after 
bond-cleavage is a high chemical potential state with bound ADP. Pi, 
shown as a hexagon. (Bottom right) Relaxation of the C-site conforma- 
tion occurs, coupled to drug movement from inside-facing, higher- 
affinity to outside-facing, lower-affinity, and P~ is released. (Bottom left) 
Drug and ADP dissociate. Drug binds at the inner side and in top I~/t 
N- and C-sites have now reversed their relationship. In the next cycle. 
ATP hydrolysis will occur in the N-site. 
which incorporates also a proposal for coupling of drug trans- 
port to ATP hydrolysis. Pgp differs from other transport 
ATPases in that it shows no high-affinity binding site tbr Mg- 
ATP, nor does it utilize a covalent E -P  catalytic intermediate. 
Changes in free energy associated with such species during the 
catalytic cycle are thought to be coupled to conformational 
changes at transport substrate binding sites in other transport 
ATPases [42]. In Pgp, P, binding occurs with relatively weak 
affinity (above), implying that a large lYee energy change occurs 
during catalysis before the stage of Pi release. We postulate 
therefore that the ATP hydrolysis step itself generates a 
Pgp' Mg-ADP" Pi conformation of high chemical potential. Re- 
laxation of this conformation, probably through intermediates. 
could be coupled to movement of a drug-binding site from 
inside-facing aspect of higher affinity to outside-facing aspect 
of lower affinity. 
8. Conclusions 
(1) Pgp is an ATPase and ATPase activity is obligatorily 
linked to conferral of MDR phenotype in cells. Both predicted 
nucleotide-binding sites bind Mg-ATP with approximately the 
same affinity, and both hydrolyze Mg-ATP. The two catalytic 
sites interact strongly and cannot hydrolyze Mg-ATP inde- 
pendently. A minimal reaction scheme for ATP hydrolysis is 
presented, and an alternating catalytic sites cycle is proposed. 
(2) Understanding coupling of ATP hydrolysis to drug trans- 
port is a major goal. We postulate that drug transport is cou- 
pled to relaxation of a high energy catalytic site conformation 
which is generated by the hydrolysis tep. (3) It is not unreason- 
able to speculate that several, perhaps most, of the ABC trans- 
porters have nucleotide-binding and ATP hydrolysis character- 
istics similar to those of Pgp. The designation of the ABC 
transporter family is based on similarity of predicted structure; 
it is important o find out whether there are also basic func- 
tional similarities. The experimental pproaches reviewed here 
may prove valuable in this regard. (4) Work on Pgp under- 
scores the concept hat transport ATPases gain a key advantage 
from the use of multiple, highly-cooperative catalytic sites re- 
acting sequentially. What the key advantage is, however, re- 
mains to be clarified. 
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